Cargando…

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kroemer, Guido, Kepp, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632107/ https://www.ncbi.nlm.nih.gov/pubmed/34858731 http://dx.doi.org/10.1080/2162402X.2021.2005859

Ejemplares similares

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

A novel platinum-based chemotherapeutic inducing immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2020)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Kroemer, Guido, et al.
Publicado: (2021)

Immunogenic cell death inducers as anticancer agents
por: Kepp, Oliver, et al.
Publicado: (2014)

Prevention and treatment of cancers by tumor antigen-expressing Staphylococcus epidermidis
por: Kepp, Oliver, et al.
Publicado: (2023)

Novel galenic formulations for delivering immunochemotherapies: kill intelligently, remove the checkpoint and let the T cells in!
por: Kepp, Oliver, et al.
Publicado: (2020)

Arsenic trioxide as an inducer of immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2023)

Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death
por: Gomes-da-Silva, Lígia C., et al.
Publicado: (2020)

TP53 and MTOR crosstalk to regulate cellular senescence
por: Galluzzi, Lorenzo, et al.
Publicado: (2010)

Ferroptosis becomes immunogenic: implications for anticancer treatments
por: Tang, Daolin, et al.
Publicado: (2020)

Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy
por: Bourgin, Melanie, et al.
Publicado: (2022)

AKT as a therapeutic target for autophagy induction and cancer therapy
por: Wu, Qi, et al.
Publicado: (2021)

An unexpected link between immunogenic cell death and inhibition of gene transcription
por: Humeau, Juliette, et al.
Publicado: (2020)

Secreted calreticulin mutants subvert anticancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2019)

Tumor-infiltrating lymphocytes for melanoma immunotherapy
por: Kepp, Oliver, et al.
Publicado: (2023)

Identification of pharmacological agents that induce HMGB1 release
por: Liu, Peng, et al.
Publicado: (2017)

Redaporfin induces immunogenic cell death by selective destruction of the endoplasmic reticulum and the Golgi apparatus
por: Gomes-da-Silva, Lígia Catarina, et al.
Publicado: (2018)

Pretreatment plasma fibrinogen and serum albumin levels predict therapeutic efficacy of concurrent radiochemotherapy for esophageal squamous cell cancer
por: Wang, Jijin, et al.
Publicado: (2022)

Immunogenic cell death in cancer: concept and therapeutic implications
por: Galluzzi, Lorenzo, et al.
Publicado: (2023)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications
por: Chen, Xiewan, et al.
Publicado: (2016)

Impact of local anesthetics on epigenetics in cancer
por: Bezu, Lucillia, et al.
Publicado: (2022)

Histamine antagonists promote cancer immunosurveillance
por: Liu, Peng, et al.
Publicado: (2023)

Elevated plasma levels of the appetite-stimulator ACBP/DBI in fasting and obese subjects
por: Li, Sijing, et al.
Publicado: (2021)

Elevated Serum Level of HMGB1 in Patients with the Antiphospholipid Syndrome
por: Manganelli, Valeria, et al.
Publicado: (2017)

Radiochemotherapy
Publicado: (1998)

Phospho-ERK1/2 levels in cancer cell nuclei predict responsiveness to radiochemotherapy of rectal adenocarcinoma
por: Holck, Susanne, et al.
Publicado: (2015)

Conventional type 1 dendritic cells (cDC1) in cancer immunity
por: Liu, Peng, et al.
Publicado: (2023)

HMGB1 in inflammation and cancer
por: Wang, Shumin, et al.
Publicado: (2020)

Immunogenic cell death in radiation therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2013)

Mitochondrial regulation of cell death: a phylogenetically conserved control
por: Galluzzi, Lorenzo, et al.
Publicado: (2016)

Mitophagy: An Emerging Role in Aging and Age-Associated Diseases
por: Chen, Guo, et al.
Publicado: (2020)

Direct Cytotoxic and Indirect, Immune-Mediated Effects of Local Anesthetics Against Cancer
por: Wu Chuang, Alejandra, et al.
Publicado: (2022)

Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis
por: Kepp, Oliver, et al.
Publicado: (2020)

Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2015)

The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer
por: Oblak, Irena, et al.
Publicado: (2013)

Metabolic Profiling of CHO Cells during the Production of Biotherapeutics
por: Coulet, Mathilde, et al.
Publicado: (2022)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Concurrent radiochemotherapy in advanced hypopharyngeal cancer
por: Krstevska, Valentina, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pmp5dokt4odqla68vkb1pgj2e4